Valar Labs

Company profile

About Valar Labs

Valar Labs is pioneering the next generation of precision oncology through AI-powered diagnostic testing. The company develops computational histology artificial intelligence (CHAI) biomarkers that analyze routine H&E stained tumor histology slides to predict treatment response and prognosticate outcomes across multiple cancer types. Their mission is to remove uncertainty from cancer treatment decisions, enabling physicians and patients to make informed choices about therapy selection rather than educated guesses. Valar Labs' flagship product, Vesta, is the world's first AI-based diagnostic test to predict treatment response in bladder cancer, specifically identifying patients likely to respond to BCG therapy. The company has validated its approach across a cohort of 1,000+ bladder cancer patients spanning four continents, with results published in peer-reviewed journals. Beyond bladder cancer, Valar Labs has demonstrated the generalizability of their AI approach to other solid tumors including prostate cancer and pancreatic cancer. The company also partners with leading pharmaceutical companies to accelerate early research, deploying AI algorithms to discover biomarkers that predict therapy response, deploy diagnostics for biomarker-associated therapies, and automate molecular biomarker screening to increase clinical trial enrollment while lowering costs. Valar Labs serves oncologists, health systems, and patients seeking to match the right treatment to the right patient at the right time.

Company description · Valar Labs official website

Mission. Our mission is to remove the uncertainty from cancer treatment decisions, so physicians and patients don't have to make educated guesses about therapy selection.